Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma.

  • Authors:
    • S G Gray
    • S Kytola
    • W O Lui
    • C Larsson
    • T J Ekstrom
  • View Affiliations

  • Published online on: January 1, 2000     https://doi.org/10.3892/ijmm.5.1.33
  • Pages: 33-74
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The Hep3B cell line analyzed in the present study is a widely used in vitro model in studies characterizing pathogenetic, functional, and therapeutic aspects of human hepatocellular carcinoma (HCC). Here we have determined the chromosomal composition using a combination of cytogenetic techniques. In agreement with the original description for this cell line, Hep3B was found to have a hypotriploid chromosome content carrying 59-63 chromosomes and no cytogenetic differences were demonstrated between early and late passages suggesting that this cell line has remained stable after repeated subculturing. Mutations and alterations of the IGF-axis as well as of chromosome 1p34, where the genes for histone deacetylase 1 (HDAC1) and transforming growth factor beta receptor interacting protein-1 (TRIP-1) map, are frequent events in hepatocarcinogenesis. This study characterizes the Hep3B cell line in detail at the karyotypic level, using comparative genomic hybridization (CGH), spectral karyotyping (SKY), G-banding and FISH techniques. We have also examined the effects of the histone deacetylase inhibitor trichostatin A (TSA) on members of the IGF-axis, and analysed them with regard to the karyotype. The results show that expression of one member of the IGF-axis, IGFBP-3, is greatly upregulated by treatment of Hep3B cells with TSA. As IGFBP-3 has been shown to induce apoptosis, these results suggest a possible use for histone deacetylase inhibitors and/or IGFBP-3 in the treatment of HCC.

Related Articles

Journal Cover

Jan 2000
Volume 5 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gray S, Kytola S, Lui W, Larsson C and Ekstrom T: Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma.. Int J Mol Med 5: 33-74, 2000.
APA
Gray, S., Kytola, S., Lui, W., Larsson, C., & Ekstrom, T. (2000). Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma.. International Journal of Molecular Medicine, 5, 33-74. https://doi.org/10.3892/ijmm.5.1.33
MLA
Gray, S., Kytola, S., Lui, W., Larsson, C., Ekstrom, T."Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma.". International Journal of Molecular Medicine 5.1 (2000): 33-74.
Chicago
Gray, S., Kytola, S., Lui, W., Larsson, C., Ekstrom, T."Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma.". International Journal of Molecular Medicine 5, no. 1 (2000): 33-74. https://doi.org/10.3892/ijmm.5.1.33